×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MDGL – madrigal pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MDGL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/14
07:36 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/14
03:01 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
1/12
09:08 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "buy" rating reaffirmed by analysts at Cowen Inc.
1/10
01:24 pm
mdgl
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility And Long Term Momentum [Yahoo! Finance]
Low
Report
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility And Long Term Momentum [Yahoo! Finance]
1/10
03:36 am
mdgl
Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe Downgrade - What's Changed [Yahoo! Finance]
Low
Report
Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe Downgrade - What's Changed [Yahoo! Finance]
1/9
08:00 am
mdgl
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor
Medium
Report
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor
1/6
07:28 pm
mdgl
Why Madrigal Pharmaceuticals Stock Slumped on Tuesday [Yahoo! Finance]
Low
Report
Why Madrigal Pharmaceuticals Stock Slumped on Tuesday [Yahoo! Finance]
1/6
09:02 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was given a new $579.00 price target on by analysts at Wolfe Research.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was given a new $579.00 price target on by analysts at Wolfe Research.
Date
Time
Symbol
Company Name
Action
%Chg
11/4/2025
07:00 am
MDGL
madrigal pharmaceuticals, inc.
MISS
Report
3.4%
madrigal pharmaceuticals, inc.
8/5/2025
07:00 am
MDGL
madrigal pharmaceuticals, inc.
BEAT
Report
-2.6%
madrigal pharmaceuticals, inc.
5/1/2025
07:00 am
MDGL
madrigal pharmaceuticals, inc.
BEAT
Report
-6.1%
madrigal pharmaceuticals, inc.
2/26/2025
07:00 am
MDGL
madrigal pharmaceuticals, inc.
BEAT
Report
6.6%
madrigal pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/12
05:01 pm
mdgl
Form SCHEDULE 13D/A Canticle Pharmaceuticals Filed by: Taub Rebecca
Low
Report
Form SCHEDULE 13D/A Canticle Pharmaceuticals Filed by: Taub Rebecca
12/12
05:00 pm
mdgl
Form SCHEDULE 13D/A Canticle Pharmaceuticals Filed by: FRIEDMAN PAUL A
Low
Report
Form SCHEDULE 13D/A Canticle Pharmaceuticals Filed by: FRIEDMAN PAUL A
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/27
Hedge Funds Are Dumping Madrigal Pharmaceuticals, Inc. (MDGL) [Yahoo! Finance News]
8.1%
11/8 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 7.3%
3/4 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 5.1%
4/17 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.1%
11/7 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) had its price target lowered by analysts at HC Wainwright from $225.00 to $215.00. They now have a "buy" rating on the stock. 5.0%
12/2 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) had its "buy" rating re-affirmed by analysts at Citigroup Inc. They now have a $166.00 price target on the stock, down previously from $173.00. 3.6%
4/3 Intercept Pharmaceuticals: Your Transformative Year [Seeking Alpha] 3.5%
6/4 Madrigal Pharmaceuticals to Present at Upcoming Investment Conferences 3.2%
5/15 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) had its "buy" rating re-affirmed by analysts at Citigroup Inc. They now have a $186.00 price target on the stock, down previously from $200.00. 3.2%
8/12 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was given a new $134.00 price target on by analysts at B. Riley. They now have a "buy" rating on the stock. 3.1%
11/8 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 7.3%
3/4 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 5.1%
4/17 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.1%
11/7 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) had its price target lowered by analysts at HC Wainwright from $225.00 to $215.00. They now have a "buy" rating on the stock. 5.0%
12/2 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) had its "buy" rating re-affirmed by analysts at Citigroup Inc. They now have a $166.00 price target on the stock, down previously from $173.00. 3.6%
4/3 Intercept Pharmaceuticals: Your Transformative Year [Seeking Alpha] 3.5%
6/4 Madrigal Pharmaceuticals to Present at Upcoming Investment Conferences 3.2%
5/15 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) had its "buy" rating re-affirmed by analysts at Citigroup Inc. They now have a $186.00 price target on the stock, down previously from $200.00. 3.2%
8/12 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was given a new $134.00 price target on by analysts at B. Riley. They now have a "buy" rating on the stock. 3.1%
TOP News Decliners
12/10
Madrigal Pharmaceuticals Announces Secondary Offering of 1,200,000 Shares of Common Stock
-16.4%
7/25 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -10.0%
4/28 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.9%
1/30 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) is now covered by analysts at Canaccord Genuity. They set a "buy" rating and a $198.00 price target on the stock. -6.6%
12/18 Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH ( -5.7%
9/25 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -5.5%
11/14 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.9%
11/6 Q3/2019 9/30/2019 EPS -1.390 ZacksConsensus -1.360 ActVsEst (0.030) - Miss -4.6%
4/14 Madrigal Pharma up 13% on positive data on NASH drug resmetirom [Seeking Alpha] -3.8%
10/29 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was upgraded by analysts at ValuEngine from a "buy" rating to a "strong-buy" rating. -3.7%
7/25 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -10.0%
4/28 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.9%
1/30 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) is now covered by analysts at Canaccord Genuity. They set a "buy" rating and a $198.00 price target on the stock. -6.6%
12/18 Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH ( -5.7%
9/25 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -5.5%
11/14 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.9%
11/6 Q3/2019 9/30/2019 EPS -1.390 ZacksConsensus -1.360 ActVsEst (0.030) - Miss -4.6%
4/14 Madrigal Pharma up 13% on positive data on NASH drug resmetirom [Seeking Alpha] -3.8%
10/29 Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was upgraded by analysts at ValuEngine from a "buy" rating to a "strong-buy" rating. -3.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: